Asfotase Alfa News
Asfotase Alfa currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Asfotase Alfa with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.
- Evidence level: L5
- Predicted indications (20):
- mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies (100.0%)
- Steel syndrome (99.9%)
- hypophosphatasia (99.9%)
- exocrine pancreatic insufficiency (99.9%)
- Scheie syndrome (99.8%)
- Hurler syndrome (99.8%)
- lysosomal storage disease with skeletal involvement (99.7%)
- familial apolipoprotein C-II deficiency (99.7%)
- esophageal varices with bleeding (99.7%)
- esophageal varices without bleeding (99.7%)
- cystinosis (99.7%)
- primary bone dysplasia (99.6%)
- lysosomal disease with hypertrophic cardiomyopathy (99.5%)
- syndromic neurometabolic disease with X-linked intellectual disability (99.5%)
- eyelids malposition disorder (99.5%)
- varicose disease (99.4%)
- growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant (99.4%)
- monosomy X (99.4%)
- primary bone dysplasia with increased bone density (99.3%)
- Sanfilippo syndrome (99.3%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.